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Abstract: Neurodegenerative diseases (NDs) are increasingly positioned as leading causes of global
deaths. The accelerated aging of the population and its strong relationship with neurodegeneration
forecast these pathologies as a huge global health problem in the upcoming years. In this scenario,
there is an urgent need for understanding the basic molecular mechanisms associated with such
diseases. A major molecular hallmark of most NDs is the accumulation of insoluble and toxic
protein aggregates, known as amyloids, in extracellular or intracellular deposits. Here, we review the
current knowledge on how molecular chaperones, and more specifically a ternary protein complex
referred to as the human disaggregase, deals with amyloids. This machinery, composed of the
constitutive Hsp70 (Hsc70), the class B J-protein DnaJB1 and the nucleotide exchange factor Apg2
(Hsp110), disassembles amyloids of α-synuclein implicated in Parkinson’s disease as well as of
other disease-associated proteins such as tau and huntingtin. We highlight recent studies that have
led to the dissection of the mechanism used by this chaperone system to perform its disaggregase
activity. We also discuss whether this chaperone-mediated disassembly mechanism could be used to
solubilize other amyloidogenic substrates. Finally, we evaluate the implications of the chaperone
system in amyloid clearance and associated toxicity, which could be critical for the development of
new therapies.
Keywords: neurodegeneration; amyloid; chaperone; disaggregase
1. Introduction: Neurodegeneration and Amyloid Deposition
Neurodegenerative diseases (NDs) have a multifactorial etiology resulting from an
intricate relationship between genetic and environmental factors [1]. A histopathological
hallmark of most NDs include the deposition of aggregated proteins called amyloids into
extracellular or intracellular inclusions [2]. The identity of the conformationally altered
protein and the anatomical brain regions and cell types affected differ depending on
the disease (Figure 1). For instance, Alzheimer´s disease (AD) is characterized by the
deposition of two distinct types of aggregates in the temporal and parietal lobes of the
brain: extracellular plaques composed of amyloid-β (Aβ) peptides (cleavage products
of the transmembrane protein APP), and intracellular neurofibrillary tangles composed
of tau proteins [3]. In Parkinson´s disease (PD), aggregates of the protein α-synuclein
(α-syn) accumulate inside dopaminergic neurons of the substantia nigra pars compacta [4].
Deposits of superoxide dismutase 1 (SOD1) [5], TAR DNA binding protein (TDP-43) [6],
RNA-binding protein FUS [7], huntingtin (Htt) [8], or PrP prion protein [9] have been
identified in different NDs (Figure 1).
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Protein misfolding and its deposition into proteinaceous aggregate inclusions have a
two-faced pathomechanism: a loss of physiological function and a gain of toxic function [10].
Misfolding and aggregation of proteins imply the loss of their native structure, and there-
fore, their physiological function. This may include loss of catalytic activity or loss of
interactions with partner proteins or ligands [11–13]. Additionally, the generation and
accumulation of misfolded protein species also involves a gain of toxic function as these
aggregation-prone species have a heightened tendency to engage in inappropriate inter-
actions with other cellular components [2]. Through both mechanisms, aggregates alter
fundamental cellular processes, ultimately leading to cell death.
2. Synucleinopathies and α-Synuclein Amyloid Formation
The synuclein family consists of three members: α-, β-, and γ-synuclein [14,15].
Since their discovery, the SNCA gene, which encodes for α-syn, has been the focus of
intensive research due to its association with neurodegeneration. α-syn is very abundant
in neurons, being primarily located at the presynaptic termini [16]. Although it represents
1% of the cytosolic proteins, α-syn can also be found bound to synaptic membranes [17].
This protein is believed to play a major role in the regulation of synaptic trafficking,
homeostasis, and neurotransmitter release by interacting with both synaptic vesicles and
synaptic proteins such as phospholipase D2, members of the RAB small GTPases family,
and SNARE complexes [18]. Other cellular processes in which α-syn is involved include
signal transduction, mitochondria functioning, and oxidative stress regulation [18].
Aggregation of α-syn into amyloid fibrils and their subsequent accumulation into
intracellular inclusions is a hallmark of many neurodegenerative disorders collectively
known as synucleinopathies (Figure 1). Within this group, dementia with Lewy bodies
(DLB), multiple system atrophy (MSA), and PD are the most common [19]. In PD and
DLB, inclusions are preferentially found inside neurons and are called Lewy bodies (LBs)
and Lewy neurites (LNs) [20], while in MSA, these inclusions are localized in glial cells as
poorly organized bundles of fibrils and are referred to as glial cytoplasmatic inclusions [21].
Although the general belief was that α-syn was the major component of these intracellular
inclusions, recent studies have revealed that their composition is highly heterogeneous,
containing cytoskeletal elements, membrane fragments, vesicles, lysosomes, mitochondria,
and other misshaped organelles [22,23]. Aggregation of α-syn plays a key role in their
formation by constituting a scaffold of fibrillated protein that sequesters all these cellular
components [24]. Although it is currently accepted that the toxicity of amyloids mainly
comes from the oligomeric species (see Section 5), formation of LB-like inclusions has
also been suggested to be a driver of neurodegeneration by disrupting cellular functions
such as organellar trafficking and inducing mitochondrial damage, all contributing to
synaptic dysfunctions [22,24].
The amyloid aggregation pathway of α-syn begins when the protein misfolds and
starts clustering. The species formed at this initial stage are composed of a small number
of molecules that normally retain the structure of the native protein, being either highly
disordered [25] or α-helix-enriched [26,27] intermediates. Only relatively weak intermolec-
ular interactions are involved within these early aggregates and thus, they are typically
unstable. However, such aggregates can undergo an internal reorganization to form more
stable species with a β-sheet secondary structure, a conversion step often accompanied
by an increase in compactness and size in a global process called nucleation [25,28]. These
β-structured aggregation nuclei (also known as seeds) can further grow by self-association
or through monomer addition (elongation or polymerization) [25,28,29] forming fibrils
with a highly regular in-register cross-β structure. Besides primary nucleation, elongation,
and self-association, other secondary processes are significant in amyloid assembly [30]. Of
particular interest are secondary nucleation reactions including fibril surface-catalyzed for-
mation of new clusters of monomers [31] and fibril fragmentation into smaller pieces [32].
Both secondary processes seem crucial in the formation of additional aggregation interme-
diates [33], which are the main cytotoxic species of the amyloid formation process [34].
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Figure 1. Protein aggregate deposition disorders affecting the nervous system. A multiplicity of proteins has been found
forming a gregate deposits in the brain of patients with NDs. Depending on the disease, the amyloidogenic protein that
forms such deposits and their location in the brain vary. A gregates of the same protein can be found in different brain
regions resulting in different disorders, as found for tau and α-syn. NDs involving the a gregation of tau or α-syn are
referred to as tauopathies and synucleopathies, respectively. This figure illustrates the main brain locations of amyloid
deposits of some amyloidogenic proteins, which may fluctuate with the progression of the disease or among patients.
3. Disaggregation of α-Synuclein Amyloids by Molecular Chaperones
Molecular chaperones are key effectors of the protein homeostasis network, guiding pro-
teins along productive folding pathways, avoiding and reversing misfolding/aggregation,
and cooperating with the degradation machinery [35]. There are several evolutionary
conserved families of molecular chaperones that are classified by their molecular weight
including the ATP-independent small heat shock (sHsps) and Hsp40 proteins and sev-
eral ATP-dependent chaperone families (Hsp60, Hsp70, Hsp90, Hsp100) [36,37]. Such a
variety allows the modulation of n tive/aggregate protein states t rough several mecha-
nisms including de novo folding, prevention of ggregation, neutralization of aggregates,
disa gregation, or protein degradation [38].
Chaperone machines known as disa gregases extract proteins from a gregates that
can either be targeted to degradation or re ctivated, sparing the energetic burden of
novel biosynthesis. Bacter a, protists, plants, and fungi possess a powerful bi-chaperone
disa gr gase composed of the ring-shaped AAA+ chaperone Hsp100 (ClpB in bacteria,
Hsp104 in yeast, s 101 in plants) and the Hsp70 system [39]. Hsp100 cooperat s with
the Hsp70 system to thread t apped olypeptides in an ATP-dependent man er through
its central pore [40–42], thereby resolving protein aggregates. Me azoan l cks Hsp100
orthologs, and thus the disaggregation activity is hiefl provided by the Hsp70 system [43].
3.1. Hsp104 Disaggregase
Hsp104, an AAA+ ATPase from yeast, is composed of six protomers that form an
offset hexameric barrel [41]. This disaggregase remodels diverse amorphous (non-amyloid)
and amyloid clients by substrate binding and translocation through its central pore [44].
Despite not being a natural substrate of Hsp104, α-syn amyloids are targeted by this
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disaggregase [44,45]. Hsp104 efficiently disassembled fibrils composed of WT α-syn or the
pathogenic point-mutants A30P and A53T [44,45]. However, it disaggregated the variant
S129E, a mimetic mutation of α-syn phosphorylated at S129, with lower efficiency [45], and
was unable to remodel the E46K pathogenic mutant [44,45]. This chaperone was also shown
to disaggregate preamyloid oligomers of α-syn A30P [45], although inactivation of two
Hsp104 subunits ablated the activity. In the case of A30P fibrils, inactivation of one subunit
was enough to hamper disassembly [44], suggesting that the highly ordered structure
of amyloids requires a global cooperative mechanism of ATP hydrolysis and substrate
binding at the six subunits to generate the force necessary to extract monomers [44]. This
is a completely different mechanism than that used to resolve amorphous aggregates, in
which Hsp104 hydrolyzes ATP in a probabilistic mode upon aggregate binding, being a
single active subunit within the hexamer enough to drive protein disaggregation [44]. The
versatility and powerful activity of Hsp104 has led us to propose its use as a therapeutic
disaggregase of α-syn and other amyloids [46].
3.2. The Human Hsp70-Based Disaggregase System
Despite the lack of an Hsp100 homologue, the mammalian cytosol possesses a potent,
ATP-dependent protein disaggregase and reactivation activity [43]. This activity was shown
to be provided by the central chaperone Hsp70 in collaboration with a specific subset of
J-domain proteins (JDPs or Hsp40s) and nucleotide-exchange factors (NEFs), a ternary
system capable of solubilizing a wide range of amorphous aggregates [43,47–49]. Regard-
ing amyloids, equimolar concentrations of the constitutive Hsp70 (HSPA8/Hsc70), the
canonical class B J-domain protein DnaJB1 (Hdj1) and the NEF of the Hsp110 family Apg2
were shown to disassemble α-syn fibrils in a timescale of weeks [50], an activity that was
further potentiated by the addition of Hsp104 [43,50] or/and the sHsp αB-crystallin [50].
A later study revealed that a chaperone complex composed solely of members of the Hsp70,
Hsp40, and Hsp110 families (henceforth called human disaggregase) was able to efficiently
reverse α-syn amyloid fibrils within hours [51]. The amount of the NEF was proposed to
be the main reason to explain the time-scale differences as substoichiometric levels of the
NEF relative to Hsc70 seem critical for good performance [47,51].
Protein disaggregation by the human disaggregase is initiated by JDPs, recognizing
and binding to protein aggregate surfaces [52]. JDPs then recruit Hsp70 to the aggregate
through the simultaneous interaction with both the substrate and Hsp70, which results
in the stimulation of ATP hydrolysis at the Hsp70 nucleotide-binding domain (NBD) [53].
ATP hydrolysis is coupled to a conformational cycle defined by a large-scale reorganization
of the Hsp70 substrate-binding domain (SBD), in which the alpha-helical lid subdomain
closes over the β-sandwich substrate binding pocket in the ADP state, resulting in substrate
capture [54,55]. Although in all JDPs the interaction of the J-domain is responsible for the
activation of Hsc70, the adjacent glycine-phenylalanine rich domain (GF) of DnaJB1 blocks
the Hsc70-binding site [56]. The interaction of a second site (at the CTDI) of DnaJB1 with
the Hsc70 C-terminal tail releases the GF-domain and therefore its inhibitory effect [56].
This auto-inhibitory regulation found in class B JDPs is not present in members of other JDP
classes and constitutes an important mechanism in the disaggregation of amyloids, favoring
a high density recruitment of Hsc70 to the aggregate surface [56]. In the absence of DnaJB1,
Hsc70 decorates the fibrils randomly [51]. However, the multivalent interaction of DnaJB1
with the fibrils allows for the organized recruitment of Hsc70 in a crowded state [57].
Crowding of Hsc70 molecules at the surface of α-syn fibrils has an initial entropic
energy barrier that is overcome by the DnaJB1-stimulated ATPase activity of Hsc70, which
slows down the dissociation of the Hsc70(ADP) state and thus, increases an order of
magnitude the affinity of the chaperone for fibrils [51,57]. Such binding reduces the confor-
mational space accessible due to an excluded volume effect caused by the physical barrier
formed by the aggregate [57]. In an attempt to restore conformational freedom, and the as-
sociated increase in entropic energy, Hsc70 applies a pulling force away from the aggregate
surface that drives aggregate dissolution [57]. This entropic pulling mechanism has also
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been used to explain Hsp70-mediated clathrin uncoating and protein translocation [58,59].
After ATP-hydrolysis, the timely release of the trapped polypeptides from the fibrils is
mediated by a NEF, which stimulates ADP exchange by ATP [60]. Rebinding of ATP and
simultaneous opening of the substrate-binding pocket dissociates substrates from Hsp70,
promoting localized polypeptide unfolding–refolding events and resetting Hsp70 for the
next cycle of substrate binding. Among the several existing Hsp70 NEFs, Bag1, Hsp105a,
and Apg2 have been shown to stimulate Hsc70-mediated disassembly of α-syn fibrils,
although with very different efficiencies (Bag1 < Hsp105a < Apg2) [51]. The higher molec-
ular mass of NEFs from the Hsp110 family (Hsp105a and Apg2) seems to be the reason
for these differences, as disassembly of amyloids is favored by a bulky NEF like Apg2,
which besides exchanging ADP by ATP, also rearranges the fibril-bound Hsc70 molecules,
increasing crowding and the formation of productive disaggregase assemblies [57].
3.3. Models for the Disassembly of Amyloids by the Human Disaggregase
From a mechanistic point of view, there is uncertainty about how human chaperones
proceed in the disassembly of amyloids. By using α-syn fibrils capped with his-tagged
protomers, Shorter and colleagues showed that Hsc70, Hdj1, and Apg2, in the presence of
HspB5, liberated only his-α-syn into the soluble fraction, which indicated that disassembly
proceeded via depolymerization [50]. A later contribution by Bukau´s group showed a
fast disappearance of longer fibrils with a concomitant appearance of shorter species in the
presence of Hsc70, DnaJB1, and Apg2, and proposed that apart from depolymerizing, the
human disaggregase could also extract monomers from the center of the fibrils, therefore
breaking them into smaller fragments [51]. This was proposed under the premise that
a depolymerization-only disassembly might be expected to decrease length at a similar
rate in all fibrils. We have recently shown that the disassembly process is the result of an
all-or-none abrupt solubilization of individual aggregates (Figure 2), which starts with the
destabilization of the fibril tips and rapidly progresses to completion through protofilament
unzipping and depolymerization [61]. The fast propagation of the solubilization process is
consistent with entropic pulling forces provided by Hsc70 crowding at the fibril surface.
Through this mechanism, the Hsc70-based system preferentially disaggregates shorter and
thus, more toxic, fibrils of α-syn into monomers, without the accumulation of new harmful
oligomeric intermediates. We also showed that this system efficiently eliminates α-syn
oligomers kinetically trapped during the self-assembly process, which are similar to the
transient oligomeric forms generated at early aggregation stages [25,62], and are especially
toxic due to their membrane binding and disruption activities [62,63]. In the case of long
fibrils, disaggregation was severely impaired, possibly due to the interruption of the fast
depolymerization process [61], which would render monomers and shorter fibrils without
altering the number of fibril ends.
Although we do not discard that the human disaggregase could eventually fragment
long fibrils of α-syn [51], we reason that its activity relies predominantly on a fast asyn-
chronous depolymerization, targeting small and toxic oligomer aggregate species (Figure 2).
This is further evidenced by the fact that the large size of Apg2 limits its ability to act on
Hsp70 molecules that are densely packed onto the fibrils [57]. Thus, due to the excluded
volume effects, the NEF activity of Apg2 could be biased to less crowded fibril regions
such as the ends. At this position, besides stimulating the exchange of ADP by ATP on
Hsc70, Apg2 could reposition the fibril-bound Hsc70 molecules in closer proximity to each
other, thus increasing the formation of productive disaggregase assemblies [57] and drive
protofibril unzipping and depolymerization [61]. A preprint work also points toward this
scenario, suggesting that Hsc70 clusters at the fibril ends where monomers are extracted,
avoiding intermediate fragmentation steps [64].
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Figure 2. Disassembly models proposed for the human disaggregase. Two depolymerization models have been proposed
for the amyloid disassembly activity of the human disaggregase machinery. The first one established that disaggregation
was expected to synchronously decrease the length at a similar rate in all fibrils, regardless of their size (a). A change
in paradigm has recently been put forward, considering the disassembly as an asynchronous process (b). In this model,
solubilization is not interpreted as a population of aggregat s with decreasing size over time, instead being considered as a
population with a decreasing number of aggregates over time. This m chanism esp cially applies for ox c oligomers/short
fibrils, being eliminated by the chaperones one by one rather than progressively reducing their size. Disassembly starts
with the destabilization of the fibril tips and rapidly progresses to completion through protofilament unzipping and
depolymerization, without accumulation of new harmful oligomeric intermediates (c). This mechanism is hampered for
large fibrils due to their increased stability and reduced number of ends, biasing the human disaggregase activity toward
small aggregate species, avoiding their toxicity and growth into less tractable species.
4. Expanding the Human Disaggregase Activity
4.1. Chaperone-Mediated Disassembly of Oth r Amyloidogenic Proteins
Even though most of the studies related to amyloid disassembly by the human dis-
aggregase published to date have focused on α-syn amyloids, this system can also revert
fibrils of other amyloidogenic proteins linked to neurodegeneration [65–67]. Huntington’s
disease (HD) is a ND ca sed by an expanded CAG trinucleotide repeat at the N-terminus
f the HTT gene that results in amyloid formation. The human dis ggregase was shown
not only to completely suppress fibrilization of HttExon1Q48, but also to solubilize Htt
fibrils in vitro [67]. More importantly, all three chaperones of the system (Hsc70, DnaJB1,
and Apg2) interacted in vivo with Htt aggregates and depletion f any of them led to
enhanced aggregation. Among the components of thi chap ron complex, the J-protein
was shown to be the concentration-limiting factor and its overexpression in HEK293T was
sufficient to strongly ameliorate HttEx n1Q97 aggregation [67].
Tau is a microtubule-associated protein encoded by th MAPT gene located at chromo-
some 17. Upon alternative mRNA splicing of this ge e, six tau is forms of differe t lengths
(352–441 amino acids) are produced [68]. Under pathological circumstances, tau proteins
fibrillate and form intracellular deposits that can be found in several NDs collectively
known as tauopathies (Figure 1). The human disaggregase has been shown to disassemble
in vitro produced fibrils from all six tau isoforms [66] and the K18 construct containing
the four microtubule-binding repeats [65]. As with α-syn and Htt, the active chaperone
complex was formed by Hsc70 and Apg2 in the presence of DnaJB1, although DnaJB4,
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another member of the class B JDPs, was equally capable of promoting disassembly of tau
1N3R fibrils [66]. Class A JDPs DnaJA1 and DnaJA2 could not assist tau disaggregation [66],
reinforcing the specificity of class B JDPs in amyloid disassembly [56]. Chaperone-mediated
disaggregation of tau fibrils occurred without fibril fragmentation and generated mainly
monomeric protein, although dimeric and tetrameric tau species were also found [66].
This is in good agreement with our data, as the disaggregation efficiency of tau 2N4R
dramatically increased upon sonication [61], suggesting a depolymerization process that
starts at the fibril ends.
4.2. Impact of Amyloid Polymorphism in Chaperone Activity
Despite the differences in the sequence of α-syn, Htt, and tau, the human disaggregase
can disassemble fibrils of the three proteins, suggesting a universal and specific targeting
mechanism toward the amyloid fold. Amyloid fibrils are characterized by an extended
β-sheet secondary structure in which individual β-strands are arranged in an orientation
perpendicular to the fiber axis, a structure known as cross-β. It is increasingly evident
that the same polypeptide sequence can adopt several pathological conformations, known
as amyloid polymorphs [69]. Polymorphs may differ in the number of protofilaments
and their organization (protofilament interface and orientation, twist-degree between
protofilaments) [70], the number of strands and the identity of the residues involved in the
cross-β structure, the orientation of the interacting β-sheets (parallel versus antiparallel
intermolecular alignment), the nature of the interactions between β-sheet layers, and the
conformation of non-β strand protein regions [71].
Different structures have been reported for WT α-syn fibrils, revealing that aggregation
might generate several polymorphs [72]. Depending on the aggregation conditions, several
polymorphs have been produced in vitro, namely 1a, 1b, 2a, or 2b [73]. In most atomic
structures known to date, fibrils with a diameter of ~10 nm are composed of two identical
protofilaments. The main differences between polymorphs are the number of β-strands,
the residues involved in their formation (Figure 3), and the amino acids that participate in
the interface between protofilaments (from 2 to 12 residues) [74,75]. Interestingly, residues
E46, H50, G51, and A53 are located at this interface in specific polymorphs (Figure 3,
interfaces highlighted in yellow), stressing the relevance of point-mutations related to
neurodegeneration in fibril formation and growth. In fact, the structures of fibrils carrying
the E46K, H50Q, and A53T disease-associated mutations have revealed that they change
the protofibril interface or even promote a different fibril fold [75–79].
Post-translational modifications (PTMs) that show different profiles among NDs could
also be implicated in the final structure of the fibril. This has been proven for tau, for
which cross-talk between PTMs influences filament structure, contributing to the structural
diversity of tauopathy strains [80]. Among the PTMs associated with α-syn, acetylation,
phosphorylation, and truncation are predominant [81–83]. Two fibril structures have
been proposed for in vitro produced acetylated α-syn fibrils with an arrangement closely
resembling that of polymorph 1a [84,85] and 2a [75]. Most of α-syn is phosphorylated at
S129 in the brain of patients that suffered from synucleinopathies [86]. Recombinantly
produced pS129 fibrils had a 2a-like structure [75]. pY39 α-syn fibrils showed a completely
different fold with a core composed of residues 1 to 100 and fibrils with either two or three
protofilaments [87]. Regarding α-syn truncation, C-terminal truncated variants presented
a similar fold to the 1a polymorph (Figure 3), but they had an increased helical twist,
generating a more packed core [84].
A recent study showed that the structure of α-syn fibrils obtained from MSA pa-
tients differs from those assembled from recombinant proteins [88]. MSA-derived fibrils
are formed by the asymmetrical packing of two pairs of different protofilaments, with a
protofilament interface spanning more than 25 residues from each non-identical protofila-
ment. In addition, a different conformer of assembled α-syn exists in DLB, although its
atomic structure has not been solved yet. Similarly, amyloid fibrils derived from post-
mortem diseased-brains have identified differently folded forms of tau [89–92]. Altogether,
Cells 2021, 10, 2745 8 of 16
these results have led to the hypothesis that each ND may be characterized by its own
unique amyloid fibril structural signature [88,93].
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The effect of amyl id polymorphism in chaperone-mediated disaggregation remains
poorly understood. Consideri g the unzipping-depolymerization disasse bly mechanism
employed by the human disaggregase [61], factors such as the number of protofilaments,
their asymmetric interaction, the interface between them and other specific structural
features could affect chaperone binding and/or disaggregation activity. Tau filaments
from Braak stage VI AD cortex grey matter prepared using sarkosyl extraction were
efficiently solubilized by the human disaggregase [66]. However, the activity of this
system to disassemble recombinantly produced C-terminally truncated α-syn fibrils was
abolished due to a deficient binding of DnaJB1 [57], indicating that some PTMs could
indeed alter the activity of chaperones. Future investigations should focus on the activity
of the human diseaggregase against disease-associated polymorphs, which could help us
to better understand the molecular basis of their contribution to pathogenesis.
5. Human Disaggregase in Amyloid Toxicity and Propagation: Friend and Foe
The toxic function of amyloids primarily arises from the intermediate oligomeric
species that populate the aggregation process [34]. Their higher hydrophobicity and
smaller size, which results in a high diffusion coefficient, allow them to establish aberrant
interactions with different cellular components and spread more readily [2]. It was initially
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proposed that amyloid deposits could be a protective mechanism to neutralize oligomeric
species and reduce their associated toxicity [94]. Nonetheless, amyloid deposits are far from
harmless and contribute to toxicity through indirect mechanisms. For instance, it has been
shown that key components of the protein homeostasis network that attempt to clear such
deposits can be sequestered, reducing the cell power to cope with aggregation [95–101].
Additionally, mature fibrils serve as a reservoir of aggregate intermediates. Although
the amyloid structure is energetically highly favorable [102], amyloid fibrils are not static
entities, but exist in equilibrium with monomeric and oligomeric species [103]. Spontaneous
fragmentation and secondary nucleation are well-established mechanisms by which mature
fibrils can generate new intermediate species [32,104–107]. Indeed, such processes seem
to play a key role in the spreading of the disease within an organism, as these small-sized
aggregates can be transmitted between cells and within organs.
Recent studies propose that the human disaggregase may also be implicated in the
prion-like propagation of amyloidogenic proteins [66,108]. Specifically, Tittelmeier et al.
showed that depletion of Hsp110 in C. elegans impaired Hsp70 disaggregation activity,
prevented re-solubilization of amorphous aggregates and compromised the overall cellular
folding capacity [108]. At the same time, knockdown of the NEF in young individuals ex-
pressing either α-syn or 35 polyglutamine (Q35) fused to Yellow Fluorescence Protein (YFP)
reduced foci formation and toxicity, and in the case of α-syn, it also diminished cell-to-cell
transmission. These results led the authors to propose that the Hsp70-based disaggregase
could promote spreading via amyloid fragmentation similarly to Hsp104, whose frag-
mentation activity [109,110] is essential for the maintenance of prions in yeast, producing
smaller seeds that are more efficiently transmitted to daughter cells [111,112]. Based on our
model [61], another possible interpretation would be an incomplete chaperone-mediated
disassembly. Although we have shown that the human disaggregase targets the most
toxic amyloid species and disassembles them through an all-or-none depolymerization
process [61], we have also observed that depolymerization of longer fibrils is not as efficient
and may be interrupted half-way through, thus producing shorter, and potentially more
toxic, species [61]. Results obtained with tau also point to this interpretation, as fragmenta-
tion was not observed for fibrils of this substrate and they were not fully disassembled,
generating soluble products (containing monomers, but also dimers and tetramers) that
seeded aggregation in P301S tau-expressing HEK293 cells [66]. Thus, the human disaggre-
gase may function as a first barrier against newly acquired oligomeric species, avoiding
their toxicity and growth into less tractable species, but overwhelming conditions for the
system could favor the aggregation cascade (Figure 4). In this context, an insufficient
amount of disaggregase relative to aggregated species might also be a determinant factor
to consider. Our group estimated that disaggregation rates of toxic oligomers and short
fibrils are rather low at α-syn:Hsc70 molar ratios higher than 2 [61], thus increasing the
half-time life of these toxic species. Induced expression of α-syn or Q35 in C. elegans [108]
might tip the scale toward the aggregate, resulting in high aggregate to chaperone ratios
and thus, slower/more inefficient disassembly by the disaggregase.
On the other hand, overexpression of Hsp110 has also been shown to be beneficial
in mice models [113,114]. Although the human disaggregase is an important factor in
amyloid clearance, in vivo, this process may be more complex due to the activity of other
branches of the proteostasis network, which may be interconnected with the Hsp70 system.
For instance, αB-crystallin might be implicated in seed spreading, although it is difficult
to assess its final effect, as has been shown to both promote [115] and inhibit [116] fibril
fragmentation. Kandasamy and Andrésson showed that yeast Hsp110 interacts with the
proteasome via its regulatory 19S particle and that NEF inhibition causes accumulation
of Hsp70-bound proteasome substrates [117]. The authors suggested a mechanism in
which Hsp110 first binds the 19S particle and then recruits the substrate-Hsp70 complex
to the proteasome, where Hsp110 promotes nucleotide exchange in Hsp70, mediating
substrate release and degradation. This finding is especially relevant considering that
N-terminal Ub modification on tau and α-syn enables proteasomes to target and remove
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their oligomeric assemblies [118]. Furthermore, the proteasome holoenzyme possesses
an ATP-dependent fibril-fragmenting activity that reduces the size of large tau and α-syn
fibrils into smaller entities [119]. Despite the key function of the proteasome in the protein
quality control network, under severe aggregation protein stress, it could play an opposite
role by fragmenting and producing more seeds in cells [120]. Autophagy has also been
shown to switch roles between seeding and aggregate clearance depending on the level of
autophagic flux [121,122].
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Figure 4. The two faces of the Hsc70-based human disaggregase. In a healthy cell state (low aggregate:disaggregase ratio;
green arrow), the human disaggregase rapidly disassemble seed-competent intermediates into the native state, avoiding
their toxic effect. Under aggregation stress (high aggregate:disaggregase ratio; red arrows), the disaggregase machinery
becomes overwhelmed and the chaperone-mediated disassembly of seed-competent intermediates slows down or is even
halte , increasing their life-span. Thus, these species are stable enough to express their toxicity via aberrant interactions
with different cellular components and spreading to neighboring cell where seeded-aggr gation is induced. Alternatively,
oligomers c n grow into large fibrils that either tend to deposit or contribute to secondary aggregation processes such
as surface-catalyzed nucleation or fibril fragmentation, functioning as a pool of new seed-competent oligomers. The
overwhelmed human disaggregase could also contribute to the production of new toxic intermediates in an attempt to
disassemble fibrils due to their incomplete depolymerization/fragmentation. Solid arrows represent processes in which the
Hsc70-based machinery is actively implicated, while dashed ones occur regardless of its disaggregase activity.
Aging is undoubtedly the major risk factor for aggregate-related diseases. Molecular
chaperones are involved in numerous cellular processes and the increasing load of mis-
folded/aggregated proteins might become overwhelming (Figure 4). This was evidenced
as the available concentration of the human disaggregase was shown to be limiting for the
suppression of fibril formation of Htt in the presence of other substrates [67]. Furthermore,
the rescue of α-syn or Q35 toxicity by the knockdown of Hsp110 observed in younger ani-
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mals was lost in older ones, suggesting that the increasing burden of endogenous misfolded
proteins that comes with age masks the chaperone-mediated promotion of α-syn and Q35
toxicity [108]. Apart from the increasing amount of aggregates, accumulating evidence
suggests a progressive deterioration of the proteostasis network with aging [123] including
a downregulation of chaperone expression [124] and the decline in both the proteasome ac-
tivity and autophagy [125,126]. The age-related increase of oxidative stress and a decrease
in mitochondrial function and ATP production could further reduce the efficiency of the
disaggregase system. Another important risk factor in NDs are aggregate-prone mutations
in amyloidogenic proteins [2], which are normally related to an early onset of the disease.
In these cases, the available chaperone pool would be at its full capacity, without the age-
related burden of cellular misfolding. However, the great amount of amyloids relative to
chaperones would favor an incomplete/slow disassembly and thus, the disaggregase could
help spreading, explaining the severity of such cases. This scenario is nicely reproduced in
young individuals of C. elegans expressing α-syn or Q35 as explained above [108]. Due to
these factors, the proteostasis network becomes progressively overwhelmed, leading to
aberrant interactions and aggregate deposition. Aggregate deposition is also a cause of
the proteostasis decline, seeding further aggregation and sequestering components of the
proteostasis network, which interferes with their standard housekeeping functions and
additionally favors aggregation. As a result, the proteostasis network drives into a vicious
cycle that ultimately leads to its collapse [35,99].
6. Conclusions and Future Perspectives
We are progressively deciphering the molecular mechanisms behind the process of
amyloid clearance. The human disaggregase is one of the key systems of the proteostasis
network that participate in this task. We advocate for a protective action of this machinery
against small amyloids, reverting their toxic effect and blocking their conversion into larger
aggregates. However, an overwhelmed disaggregase system could have the opposite effect,
leading to long-lived, partial disassembly products that could feedback aggregation within
the same cell or spread to neighboring ones. In the cellular context, toxicity and prion-like
propagation of amyloids could be the combination of multiple intricate sources including
not only chaperones, but also the protein degradation systems (proteasome and autophagy).
Future investigations should account for the relationship of the different components of the
proteostasis network in handling amyloidogenic substrates. In addition, given the multiple
fibril polymorphic structures reported to date and the association of some of them with
a specific neuropathology, forthcoming research should focus on the impact of amyloid
polymorphism in the activity of the different modulators of aggregation/disaggregation.
Along these lines, we will gain a better understanding of the molecular determinants
of amyloid formation/clearance and toxicity/propagation, which could in turn help us
identify new therapeutic targets.
The possibility of enhancing the activity of the human disaggregase as a therapeutic
approach is not straightforward, as it must be balanced and ensure that aggregate solubi-
lization is a fast reaction free of potentially toxic intermediates. An activated disaggregase
would promote this situation but, as reported for Hsp104, a strong activity could also un-
fold non-pathogenic proteins, and therefore be toxic, especially if the concentration of the
target substrate protein(s) decreases [127]. It would also be desirable to enhance the activity
of the specific chaperone-cochaperones combinations involved in the disaggregation of a
specific substrate protein, a task that is far for being achieved for the human disaggregase
and has started to be developed for Hsp104 [46,128]. This could be accomplished by engi-
neering new chaperones/cochaperones that recognize certain substrates and/or by small
molecules that favor specific interactions between the components of the disaggregase and
activate the complex. These strategies could be used alongside conventional inhibitors of
amyloid aggregation. For instance, trodusquemine, a naturally-occurring aminosterol, can
not only inhibit primary and secondary aggregation processes [129], but also effectively
suppresses the toxicity of α-syn and Aβ oligomers [129,130]. Similarly, several α-helical
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peptidic scaffolds have been found to abrogate oligomer-induced cell damage without
interfering with the native function of α-syn [131]. These compounds could avoid the
deleterious impact of the disaggregases, neutralizing the toxic, seed-competent species
released during the disassembly process. Such combinatorial therapeutic strategies could
suppose a new tool against increasingly prevalent NDs.
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